GREY Grey Global Grp. (MM)

Grey Healthcare Group Wins Worldwide Business for EXUBERA(R), Pfizer and Aventis' Inhaled Insulin for the Treatment of Diabetes NEW YORK, Sept. 23 /PRNewswire-FirstCall/ -- Grey Healthcare Group (GHG) was named Agency of Record for EXUBERA(R), an inhaled insulin that is being developed for use in patients with type 1 and type 2 diabetes through a collaboration between Pfizer and Aventis, part of the sanofi-aventis Group. GHG will manage the professional promotion for EXUBERA in a strategic, fully- integrated series of programs around the world. Financial details of the assignment were not disclosed. "We are very proud to be working with Pfizer and Aventis on EXUBERA," says Jane Parker, Group President, Grey Healthcare Group Worldwide. "Working on such an important assignment will deepen an already good relationship with two very active and important clients." Headquartered in New York, GHG comprises 10 companies with 42 offices in 16 countries. GHG provides an extensive array of integrated services in support of brand acceleration and sales that include branding, advertising, CME, medical education, direct-to-consumer/direct-to-patient communications, managed markets, e-marketing, consumer healthcare research, and contract sales. Grey Healthcare Group is a wholly owned partner company of Grey Global Group (NASDAQ:GREY), the world's seventh largest holding agency. DATASOURCE: Grey Healthcare Group CONTACT: Wendy Hauser, Dir, Corp Comm, GHG Inc., +1-212-886-3058,

Copyright